The chronic inflammatory state in hidradenitis suppurativa (HS) may result in development of clonal immune cell populations which give rise to malignant lymphomas. Our objective was to investigate prevalence of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and cutaneous T-cell lymphoma (CTCL) among patients with HS.
Results | We identified 62 690 patients with HS whose demographic characteristics are described in Table 1 (25.6% men and 74.4% women). Crude prevalences of NHL, HL, and CTCL among patients with HS compared with patients without HS (N = 28 937 880) were 0.40% vs 0.35%, 0.17% vs 0.09%, and 0.06% vs 0.02%, respectively ( Table 2) . In multivariable analysis, patients with HS had increased overall odds of having NHL (odds ratio [OR], 2.00; 95% CI, 1.76-2.26), HL (OR, 2.21; 95% CI, 1.83-2.68), and CTCL (OR, 4.31; 95% CI, 3.09-6.01).
Subgroup lymphoma prevalences are shown in Table 2 . Males with HS had higher prevalences of NHL, HL and CTCL; crude prevalences in males with HS compared with females with HS were 0.62% vs 0.32% for NHL, 0.28% vs 0.13% for HL, and 0.09 vs 0.04% for CTCL. Significant effect modification was observed in the association between HS and HL across sex subgroups. For example, the ORs for the association between HS and HL were higher in males (OR, 2.97; 95% CI, 2.22-3.99) than in females (OR, 1.86; 95% CI, 1.44-2.39) (P = .02). Patients with HS aged 65 years or older had higher prevalences of NHL and CTCL than those aged 45-64 or 18-44 years. Prevalence of NHL was 1.2%, 0.52%, and 0.20% for patients with HS aged 65 years or older, 45-64 years, and 18-44 years, respectively. Prevalence of CTCL was 0.17%, 0.07%, and 0.03% for patients with HS aged 65 years or older, 45-64 years, and 18-44 years, respectively. Age was a significant effect modifier in the association between HS and NHL. Patients with HS aged 18-44 years had 3.64 (95% CI, 2.87-4.60) times the odds of NHL compared with patients without HS in the same age-group. Patients w ith HS aged 45-64 years (OR, 1.38; 95% CI 1.09-1.74) and greater than or equal to 65 years (OR, 1.99; 95% CI, 1.65-2.41) also had increased odds of NHL compared with patients without HS of the same age-group (P < .001 for the interaction of HS with age). Overall and subgroup associations between HS and lymphoma subtypes have not been evaluated previously in a population. A single-center retrospective series identified 1776 patients with HS in whom frequency of unspecified lymphoma was 1.8%. 5 In a Swedish retrospective analysis including 2119 patients hospitalized for HS, 6 cases of any hematopoietic cancer, which may include lymphomas, were identified. 6 Neither study observed greater risk of malignant lymphoproliferative disease among patients with HS. A limitation of our study was that we could not assess the disease duration or severity in this claims analysis. The uncommonness of the event did not permit us to evaluate systemic treatment or other exposures and the association between HS and lymphoma. To our knowledge, this is the first investigation to systematically evaluate this association in a US population of patients with HS. Size and diversity of our cohort may overcome selection biases and limitations inherent to smaller cohorts recruited with specialty centers.
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